Glenmark’s PMS study allays concerns on use of Favipiravir for Covid-19 treatment
These were the findings of the Post Marketing Surveillance (PMS), study of Favipiravir (FabiFlu) on over 1000 patients
These were the findings of the Post Marketing Surveillance (PMS), study of Favipiravir (FabiFlu) on over 1000 patients
The study was conducted in patients with mild to moderate COVID-19
First company in the world to launch Ryaltris-AZ, as a novel fixed dose combination of Mometasone furoate 50 mcg + Azelastine 140 mcg
Subscribe To Our Newsletter & Stay Updated